Market Place
Sourcing Support
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though
BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch
Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. W
FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024
The year 2024 was marked by some landmark drug approvals in the areas of schizophrenia, metabolic dy
BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans
Over
the last two years, there has been a significant surge in layoffs by
pharmaceutical and biote
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
Big Pharma bets big on AI’s US$ 148 bn potential to revolutionize healthcare industry
Artificial intelligence (AI) is changing the world and bringing
efficiencies across all industries.
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
